FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
Pulte ED et al. Oncologist. 2018 Feb 7. pii: theoncologist.2017-0440. doi: 10.1634/theoncologist.2017-0440. [Epub ahead of print].

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Richardson PG et al. Br J Haematol. 2018 Feb 13. doi: 10.1111/bjh.15058. [Epub ahead of print].

Selinexor and dexamethasone in multiple myeloma.
Burki TK. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30089-5. doi: 10.1016/S1470-2045(18)30089-5. [Epub ahead of print].

Current developments in immunotherapy in the treatment of multiple myeloma.
Köhler M et al. Cancer. 2018 Feb 6. doi: 10.1002/cncr.31243. [Epub ahead of print].

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT et al. J Clin Oncol. 2018 Jan 30:JCO2017755207. doi: 10.1200/JCO.2017.75.5207. [Epub ahead of print].